Assessment of Side Effects in Patients With Chronic Hepatitis C Receiving Combination Therapy

Gastroenterology Nursing

Volumn 24, Issue 4, 2001, Pages 192-196

  Zucker, Donna M ^a   Miller, Barry W ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; ANTIVIRUS AGENT; RIBAVIRIN;

ADULT; ARTICLE; DRUG COMBINATION; FEMALE; HEPATITIS C; HUMAN; MALE; PILOT STUDY; RETROSPECTIVE STUDY; UNITED STATES;

ADULT; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; MALE; NEW ENGLAND; PILOT PROJECTS; RETROSPECTIVE STUDIES; RIBAVIRIN;

EID: 0035411143     PISSN: 1042895X     EISSN: 15389766     Source Type: Journal    
DOI: 10.1097/00001610-200107000-00007     Document Type: Article

References (19)

1. Bender, C. M., Monte. E. J., & Kerr, M. E. (1996). Potential mechanisms of interferon neurotoxicity. Cancer Practice, 4, 35-39.
2. Bonkovsky, H. L., Stefancyk, D., Leclair, P., Zucker, G. M., Israel, J., Stagias, J. G. & Farkas, P. S. (1999). Low doses of ribavirin are superior to high doses with interferon from chronic hepatitis C: Results of a controlled, randomized, multi-center trial. Poster proceedings AASLD Abstracts. Hepatology, 30(4), pt. 2, p. 265A.
3. Burton, J. R., Stoutenburg, A., & Shaw-Stiffel, T. (2000). Effect of initial treatment of chronic hepatitis C with interferon-alfa 2 b and ribavirin on health-related quality of life. Published proceedings, Schering Hepatitis Investigators Network (SHINE), February, 10-13. Fort Lauderdale, FL.
4. Clark, C., Mahoney, J., & Ghalib, R. (2000). Prevalence and incidence of high depressive symptoms in patients with chronic hepatitis C using the Center for Epidemiologic Studies Depression Scale (CES-D). Published proceedings, Schering Hepatitis Investigators Network (SHINE), February 10-13. Fort Lauderdale, FL.
5. Davis, G. L., Esteban-Mur, R., Rustgi, V., Hoefs, J., Gordon, S. C., Trepo, C., Shiffman, M. L., Zeuzem, S., Craxi, A., Ling, M., & Albrecht, J. for the International Hepatitis Interventional Therapy Group (1998). Interferon Alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. New England Journal of Medicine, 339(21), 1493-1499.
6. Dieperink, E. W., Willenbring, M. L., Tetrick, L., Thuras, P. & Ho, S. B. (2000). A prospective evaluation of neuropsychiatric symptoms in patients with hepatitis C treated with interferon alfa-2b and ribavirin. Published proceedings, Schering Hepatitis Investigators Network (SHINE), February 10-13. Fort Lauderdale, FL.
7. Haeuber, D. (1995). The flu-like syndrome. In P. T. Reiger (Ed.), Biotherapy: A comprehensive overview (pp.243-258) Boston: Jones and Bartlett.
8. Lenz, Pugh, Milligan, Gift & Suppe. (1997). The middle-range theory of unpleasant symptoms: An update. ANS, 19(3), 14-27.
9. Lenz, Suppe, Gift, Pugh, & Milligan (1995). Collaborative development of middle-range theory: Toward a theory of unpleasant symptoms. ANS, 17(3):1-13.
10. Miller, A. B., Hoogstraten, B., Staquet, M. & Winkler, A. (1981). Reporting results of cancer treatment. Cancer, 47(1). 210-211.
11. National Institutes of Health Consensus Development Conference Panel Statement: Management of Hepatitis C. (1997). Hepatology, 26: Suppl 1:2S-10S.
12. Piper, B. F., Rieger, P. T., Brophy, L., Haeuber, D., Hood, L. E., Lyver, A., & Sharp, E. (1989). Recent advances in management of biotherapy-related side effects: Fatigue. Oncology Nursing Forum, 16, 27-34.
13. Reiger, P. T. (1995). Interferon-alpha: A clinical update. Cancer Practice, 3, 356-365.
14. Rust, D. M., & Rosenzweig, M. Q. (1997). Fatigue assessment and management of patents receiving biotherapy: Relevance to clinical practice. Biotherapy: Considerations for Oncology, 2(1), 6-10.
15. Sandstrom, K. S. (1996). Nursing management of patients receiving biological therapy. Seminars in Oncology Nursing, 12, 152-162.
16. Tine, Magrin, Craxi & Paliaro (1991). Interferon for nonand non-B chronic hepatitis: A meta analysis of randomized clinical trials. Journal of Hepatology, 13:192-199.
17. Skalla, K. & Rieger, P. T. (1995). Fatigue. In P. T. Rieger (Ed.), Biotherapy: A comprehensive overview (pp.221-242) Boston: Jones and Bartlett.
18. Valentine, A. D., Meyers, C. A., Kling, M. A., Richelson, E. & Hauser, P. (1998). Mood and cognitive side effects of interferon-alfa therapy. Seminars in Oncology, 25(1), 39-47.
19. Wong, P. W., Lawitz, E., Cantu, N. S., Kadukia, S. & Maydonovitch, C. L. (2000). Screening and treatment of depression in chronic hepatitis C patients receiving interferon alfa-2b and ribavirin therapy. Published proceedings, Schering Hepatitis Investigators Network (SHINE), February 10-13. Fort Lauderdale, FL.